Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
for Metastatic Digestive System Neuroendocrine Tumor G1
33 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT05773274·Phase 2·Recruiting